FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy
The University of Melbourne · Peter MacCallum Cancer Centre · +4 more institutions
Abstract
Abstract Chimeric antigen receptor (CAR) T cell therapy has transformed the treatment of haematological malignancies such as acute lymphoblastic leukaemia, B cell lymphoma and multiple myeloma 1–4 , but the efficacy of CAR T cell therapy in solid tumours has been limited 5 . This is owing to a number of factors, including the immunosuppressive tumour microenvironment that gives rise to poorly persisting and metabolically dysfunctional T cells. Analysis of anti-CD19 CAR T cells used clinically has shown that positive treatment outcomes are associated with a more ‘stem-like’ phenotype and increased mitochondrial mass 6–8 . We therefore sought to identify transcription factors that could enhance CAR T cell…
Citation impact
- FWCI
- 52.39
- Percentile
- 100%
- References
- 71
Authors
38- JDJack D. ChanCorresponding
The University of Melbourne, Peter MacCallum Cancer Centre
- CSC. Scheffler
The University of Melbourne, Peter MacCallum Cancer Centre
- IMIsabelle Munoz
The University of Melbourne, Peter MacCallum Cancer Centre
- KSKevin Sek
The University of Melbourne, Peter MacCallum Cancer Centre
- JNJoel N. Lee
The University of Melbourne, Peter MacCallum Cancer Centre
Topics & keywords
- Chimeric antigen receptor
- Cancer research
- Phenotype
- CD19
- Biology
- Stem cell
- Lymphoma
- Cell therapy
- Good health and well-being